“GlycosBio is at the forefront of the industry with a platform that offers a transformative shift in the way producers develop, manage and deliver biochemicals and biofuels." Rob Toker, VP, Partnerships and Market Research, GlycosBio
Houston, TX (PRWEB) September 22, 2010
Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today announced the addition of Rob Toker to the management team as Vice President of Partnerships and Market Research. In his new role at GlycosBio, Toker will be responsible for the company’s overall partnership strategy and the related international market research required to successfully deploy GlycosBio’s technology worldwide. Toker will also be focused on feedstock and commodity market analysis, negotiation and contracting.
“Rob brings a tremendous amount of industry and business expertise to GlycosBio,” said Rich Cilento, Chief Executive Officer for Glycos Biotechnologies. “His in-depth knowledge of the renewable energy markets and biotechnology, not just in the U.S. but also abroad, will have a significant impact on the company’s go-to-market planning, product development and operational strategies. Additionally, Rob will help the company seek out new business opportunities to expand and bring GlycosBio’s microbial platform to producers worldwide. We’re excited to have Rob join the team.”
Prior to joining GlycosBio, Toker was Senior Vice President with Sindicatum Carbon Capital (SCC), a London – Singapore based clean energy developer and investment firm backed by Citigroup Alternative Investment and Black River (Cargill). While at SCC, Rob had a broad range of responsibilities working closely with project partners and hosts from origination, planning, financial and strategic analysis through structuring and financial close to ensure appropriate technology was integrated efficiently and deployed on time and on budget. Before joining SCC, Toker was Head of Trade and Investment in Houston for UK Trade & Investment. In addition to leading the regional team, Toker led the Houston-based International Energy Team and the Miami-based Trade and Investment team including the Latin American and Caribbean Market Intelligence Unit. While at UK Trade & Investment, Toker was also responsible for the conceptualization and execution of the industrial biotechnology market strategy for the trade and investment network which systematically linked bio-energy research and development strengths in the United Kingdom with those in the Southern U.S. and Latin America. These activities linked life sciences, energy and finance expertise producing several commercially financeable, and economically viable renewable energy projects. Toker started his career at the United Nations in New York.
“GlycosBio is at the forefront of the industry with a platform that offers a transformative shift in the way producers develop, manage and deliver biochemicals and biofuels,” said Toker. “The breadth and reach of GlycosBio’s microbial platform offers producers worldwide the opportunity to expand their product portfolio and increase their product yields, ultimately enabling them to succeed and gain competitive differentiation. I’m happy to be able to join GlycosBio at such a momentous time and look forward to helping the team continue its’ success.”
In addition to his resume credentials, Toker is also active in the energy investment community sitting on The Rice Alliance for Entrepreneurship and Technology advisory board; the University of Texas System Technology Transfer advisory board; the Greater Houston Partnership (GHP) Carbon Trading Task Force; and the Houston Technology Center (HTC) Energy Steering Committee. Toker is also a frequent presenter and occasional author. His published works include a 2008 Harvard Business Review (HBR) article “Start Thinking about Carbon Assets – Now” and a 2009 HBR article “Can Technology Really Save us from Climate Change”.
About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non food-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol. By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non-food energy balance savings to the chemical and biofuel industries. GlycosBio is privately held with established global relationships focused on product commercialization. For more information, visit http://www.glycosbio.com.